AstraZeneca has denied news reports it’s involved in talks with U.S. authorities about an emergency use authorization for its COVID-19 vaccine candidate.
The denial comes after recent news reports claiming the Trump administration is eyeing a plan to fast-track the vaccine candidate, AZD1222, before the upcoming Nov. 3 presidential election.
“AstraZeneca has not discussed emergency use authorization with the U.S. government, and it would be premature to speculate on that possibility,” AstraZeneca spokesperson Brendan McEvoy told MassDevice’s sister site Drug Discovery and Development via email.